What is the NOVELTY study?
The NOVEL observational longiTudinal studY (NOVELTY) is a global, prospective, 3-year observational study of patients with a diagnosis or suspected diagnosis of asthma and/or chronic obstructive pulmonary disease (COPD).
NOVELTY aims to describe patient characteristics, treatment patterns and disease burden over time across the spectrum of obstructive lung disease, providing real-world evidence to advance the development of precision medicine to deliver the right treatment to the right patient at the right time. The NOVELTY study is sponsored by AstraZeneca.
The NOVELTY website
Watch our short animation to learn more about the NOVELTY study
NOVELTY study infographic